Centocor To Report ReoPro Data In MI
Shares in Centocor are on the rise in expectation of data from a trialof its glycoprotein IIb/IIIa antagonist ReoPro (abciximab) in patients with myocardial infarction, scheduled to take place at the American Heart Association meeting this week. Details of this MI study will be included in a forthcoming issue of the Marketletter.
Meanwhile, Eric Hecht of Merrill Lynch believes that Centocor will file for approval of its antitumor necrosis factor antibody Avakine (infliximab) for Crohn's disease in the USA before the end of the year, and that Phase II data on the product's use in rheumatoid arthritis would be presented at the American College of Rheumatology meeting, just after the Marketletter went to press.
Joyce Lonergan and David Stone of Cowen & Co are expecting sales of $35 million in 1998 for Avakine, rising to $335 million in 2001.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze